Brian Schwartz
4PUBLICATIONS
17CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (4)
Sort by Publication Date:
|Nov 06, 2023
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma.Jennifer A Woyach, Deborah M Stephens, Ian W Flinn
|Feb 05, 2020
Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092).Leslie G Biesecker, Matthew Edwards, Sheridan O'Donnell
|Nov 07, 2018
Miransertib (ARQ 092), an orally-available, selective Akt inhibitor is effective against Leishmania.Devki Nandan, Naixin Zhang, Yi Yu
|Aug 11, 2018
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.Sean D Reiff, Rose Mantel, Lisa L Smith
Pageof 1
Frequent Collaborators
1 joint publications
Neil E Reiner
1 joint publications
Matthew Edwards
1 joint publications
Jennifer A Woyach
1 joint publications
Deborah M Stephens
1 joint publications
Ian W Flinn
1 joint publications
Seema A Bhat
1 joint publications
Ronald E Savage
1 joint publications
Feng Chai
1 joint publications
Sudharshan Eathiraj
1 joint publications
Sean D Reiff
